肝癌具有易复发及转移的特点，目前尚缺乏有效的治疗方法，导致死亡率极高。因此，如能有效地监测肝癌的发生、发展以及治疗过程，将非常有必要，对提高病人的存活率意义重大。新生血管的生成被认为与肝癌的生长密切相关，VEGF作为一种促新生血管生成因子，被发现在肝癌组织大量表达，通过抑制VEGF的活性，将能有效的遏制肝癌的发展。基于VEGF与肝癌的病理学发展的相关性，VEGF也具有作为一个有效的靶点进行肝癌显像的特性。本课题试图通过一种有潜力的VEGF抗体Bevacizumab，借助肿瘤预定位的策略，采取PET显像的方式，实现高靶向、低组织放射性辐射的肝癌功能显像，从而为及时肝癌定位以及疗效监测做出有效的判断，制定出更有效的治疗方案。

Hepatoma shows high mortality due to its high recurrence, intrahepatic metasis and lack of sufficient therapy method. It's critical to monitor initialization, development of hepatoma and therapy effect in an effective way, which will help to improve the survival rate of patients.Hepatoma carcinomas rely on angiogenesis,VEGF as an important growth factor in tumor angiogenesis correlates well with pathology process of hepatoma.Therefore,VEGF could be considered as an effective target for hepatoma imaging based on its relationship with hepatoma. It's anticipated to achieve a high tumor targeting, low background PET image of hepatoma by virtue of anti-VEGF antibody(Bevacizumab) pretargeting strategy,accordingly delivering an effective therapy to patients and improving survival rate.